Vogt Alexander, Dutzmann Jochen, Nußbaum Michael, Hoyer Daniel, Tongers Jörn, Schlitt Axel, Sedding Daniel, Plehn Alexander
Department of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Department of Cardiology and Diabetes, Paracelsus-Harz-Clinic Bad Suderode, Quedlinburg, Germany.
Front Cardiovasc Med. 2023 Jun 19;10:1210801. doi: 10.3389/fcvm.2023.1210801. eCollection 2023.
Renal sympathetic denervation (RDN) has been shown to lower arterial blood pressure both in the presence and in the absence of antihypertensive medication in an observation period of up to 3 years. However, long-term results beyond 3 years are scarcely reported.
We performed a long-term follow-up on patients who were previously enrolled in a local renal denervation registry and who underwent radiofrequency RDN with the Symplicity Flex® renal denervation system between 2011 and 2014. The patients were assessed to evaluate their renal function by performing 24-hour ambulatory blood pressure measurement (ABPM), recording their medical history, and conducting laboratory tests.
Ambulatory blood pressure readings for 24 h were available for 72 patients at long-term follow-up (FU) [9.3 years (IQR: 8.5-10.1)]. We found a significant reduction of ABP from 150.1/86.1 ± 16.9/12.0 mmHg at baseline to 138.3/77.1 ± 16.5/11.1 mmHg at long-term FU (< 0.001 for both systolic and diastolic ABP). The number of antihypertensive medications used by the patients significantly decreased from 5.4 ± 1.5 at baseline to 4.8 ± 1.6 at long-term FU ( < 0.01). Renal function showed a significant but expected age-associated decrease in the eGFR from 87.8 (IQR: 81.0-100.0) to 72.5 (IQR: 55.8-86.8) ml/min/1.73 m (< 0.01) in patients with an initial eGFR > 60 ml/min/1.73 m, while a non-significant decrease was observed in patients with an initial eGFR < 60 ml/min/1.73 m at long-term FU [56.0 (IQR: 40.9-58.4) vs. 39.0 (IQR: 13.5-56.3) ml/min/1.73 m].
RDN was accompanied by a long-lasting reduction in blood pressure with a concomitant reduction in antihypertensive medication. No negative effects could be detected, especially with regard to renal function.
肾交感神经去支配术(RDN)已被证明,在长达3年的观察期内,无论是否使用抗高血压药物,均可降低动脉血压。然而,关于3年以上的长期结果鲜有报道。
我们对先前纳入当地肾去神经支配登记处且在2011年至2014年间使用Symplicity Flex®肾去神经支配系统接受射频RDN的患者进行了长期随访。通过进行24小时动态血压测量(ABPM)、记录病史和进行实验室检查来评估患者的肾功能。
72例患者在长期随访(FU)[9.3年(四分位间距:8.5 - 10.1)]时有24小时动态血压读数。我们发现,平均血压从基线时的150.1/86.1 ± 16.9/12.0 mmHg显著降至长期随访时的138.3/77.1 ± 16.5/11.1 mmHg(收缩压和舒张压ABP均<0.001)。患者使用的抗高血压药物数量从基线时的5.4 ± 1.5显著降至长期随访时的4.8 ± 1.6(<0.01)。对于初始估算肾小球滤过率(eGFR)>60 ml/min/1.73 m²的患者,肾功能显示eGFR随年龄显著下降,从87.8(四分位间距:81.0 - 100.0)降至72.5(四分位间距:55.8 - 86.8)ml/min/1.73 m²(<0.01),而对于初始eGFR<60 ml/min/1.73 m²的患者,在长期随访时观察到无显著下降[56.0(四分位间距:40.9 - 58.4)对比39.0(四分位间距:13.5 - 56.3)ml/min/1.73 m²]。
RDN伴随着血压的长期降低以及抗高血压药物的使用减少。未检测到负面影响,尤其是在肾功能方面。